Participating in this study does not replace or change your regular medical care. Your participation in the study is expected to last up to 5 years since the start of your treatment with Oxbryta or from the date you sign the consent form.

Will my privacy be protected?

All personal and medical information will be kept strictly confidential. Information about your health while you are enrolled in PROSPECT will be kept anonymous and any identifying information will not be used.

Who can participate in the PROSPECT Registry?

You may be able to join the PROSPECT Registry if you or your child:

- Have been diagnosed with SCD and prescribed Oxbryta for you condition.

If you have questions about the study, please talk to the Study Doctor.

PROSPECT Doctor's Name

Study Coordinator's Name

Office Phone Number

PROSPECT

A Registry to Evaluate Long-Term Safety and Effectiveness of Oxbryta® in Patients with Sickle Cell Disease

Patient Information Pamphlet

Approved by Sterling IRB, IRB ID: 8694

v2.0_22Aug2022

What is the PROSPECT Registry?

PROSPECT is an observational research study to collect information on the long-term safety of Oxbryta® (voxelotor) in patients with sickle cell disease (SCD) under real-world conditions. The study is being conducted by Global Blood Therapeutics, Inc. the manufacturer of Oxbryta. Oxbryta is a medicine that has been approved in the United States to treat SCD in adults and pediatric patients 4 years of age and older.

SCD is an inherited blood disorder that worsens over time if left untreated. This research study will collect long-term safety information (including any potential side effects) for the drug Oxbryta in patients with SCD under real-world conditions.

This is an observational study, which means you will continue to receive care as decided by your healthcare provider(s). Your treatment will not change in any way as a result of your participation in this study.

Why should I participate in PROSPECT?

You are being asked to participate in this research study because you or your child have been diagnosed with SCD and;

- You or your child are already currently taking Oxbryta;

OR

- You or your child have been prescribed and will initiate treatment with Oxbryta.

Your participation is voluntary and you are free to withdraw at any time, without giving any reason, without your medical care or legal rights being affected. Information obtained from this study may assist healthcare providers and patients with SCD, when weighing the benefits and/or risks of taking Oxbryta.

PROSPECT

A Registry to Evaluate Long-Term Safety and Effectiveness of Oxbryta® in Patients with Sickle Cell Disease

How do I enroll?

To learn more about the study and to find out if you or your child qualify for the study, talk to your Study Doctor or Study Staff.

If you are eligible and would like to participate, you will be asked to provide informed consent to acknowledge your understanding of the study and to provide your permission for your personal information to be collected. After consent is received, a study representative will contact your healthcare provider to confirm your personal health information.

What is an Informed Consent Form (ICF)?

The Informed Consent Form (ICF) describes the study and any potential risk or benefits of participation. The Study Team will answer any questions you may have. By signing the form, you agree to be part of the study.

What will my participation involve once I am enrolled?

Oxbryta is not provided to you as part of this study. Your prescription for Oxbryta is independent of your participation in this study.

Approved by Sterling IRB, IRB ID: 8694